Jennane Selim, Amelal Sanae, El Mehdi Mahtat, Ahid Samir, Messaoudi Nezha, Doghmi Kamal, Mikdame Mohammed
Tunis Med. 2016 Aug-Sep;94(8-9):541-545.
Prognostic scores are an indispensable tool in the management of myelodysplastic syndromes.
Identify prognostic factors influencing overall survival of patients with myelodysplastic syndromes.
We included all patients with myelodysplastic syndromes treated in the clinical hematology department of the military hospital of Rabat (Morocco).
Seventy-four patients were included. The sex ratio [M / F] was 1.8. The median age was 65.5 years. The median follow-up was 45 months. The karyotype prognostic was good in 74%. In univariate analysis, prognostic factors influencing overall survival are: Age (p = 0.024), karyotype (p = 0.033), rate of bone marrow blasts (p = 0.002), transfusion dependence (p = 0.002), number of cytopenias (p = 0.001), hemoglobin (p = 0.009) and neutrophil count (p = 0.003). In multivariate analysis the only prognostic factor that influenced overall survival was the karyotype (p = 0.036). Transfusion dependence (p = 0.072) and the rate of marrow blasts (p = 0.107) was close to significance. The WHO Prognostic Scoring System (WPSS), the International Prognostic Scoring System (IPSS) and the Revised International Prognostic Scoring System (RIPSS) influence overall survival with a statistical significance (p <0.001).
Our study confirms the prognostic value of the karyotype and validated the WPSS, the IPSS and the RIPSS scores as significant predictors of overall survival in Moroccan patients with myelodysplastic syndromes.
预后评分是骨髓增生异常综合征治疗中不可或缺的工具。
确定影响骨髓增生异常综合征患者总生存期的预后因素。
我们纳入了在拉巴特(摩洛哥)军事医院临床血液科接受治疗的所有骨髓增生异常综合征患者。
共纳入74例患者。男女比例[男/女]为1.8。中位年龄为65.5岁。中位随访时间为45个月。核型预后良好的占74%。单因素分析中,影响总生存期的预后因素有:年龄(p = 0.024)、核型(p = 0.033)、骨髓原始细胞比例(p = 0.002)、输血依赖(p = 0.002)、血细胞减少数量(p = 0.001)、血红蛋白(p = 0.009)和中性粒细胞计数(p = 0.003)。多因素分析中,唯一影响总生存期的预后因素是核型(p = 0.036)。输血依赖(p = 0.072)和骨髓原始细胞比例(p = 0.107)接近显著水平。世界卫生组织预后评分系统(WPSS)、国际预后评分系统(IPSS)和修订的国际预后评分系统(RIPSS)对总生存期有统计学意义的影响(p <0.001)。
我们的研究证实了核型的预后价值,并验证了WPSS、IPSS和RIPSS评分作为摩洛哥骨髓增生异常综合征患者总生存期的重要预测指标。